Erin Ann Bohula May, D.Phil., M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Simvastatin | 10 | 2019 | 360 | 3.180 |
Why?
|
| Anticholesteremic Agents | 12 | 2020 | 979 | 2.520 |
Why?
|
| Coronary Care Units | 5 | 2020 | 214 | 2.180 |
Why?
|
| Acute Coronary Syndrome | 14 | 2019 | 2337 | 2.090 |
Why?
|
| Benzazepines | 5 | 2019 | 326 | 1.920 |
Why?
|
| Shock, Cardiogenic | 5 | 2020 | 688 | 1.530 |
Why?
|
| Cholesterol, LDL | 9 | 2020 | 2356 | 1.150 |
Why?
|
| Myocardial Infarction | 12 | 2020 | 11727 | 1.090 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 9 | 2018 | 3255 | 1.060 |
Why?
|
| Anti-Obesity Agents | 2 | 2018 | 217 | 1.010 |
Why?
|
| Intra-Aortic Balloon Pumping | 3 | 2020 | 219 | 0.970 |
Why?
|
| Hypolipidemic Agents | 2 | 2019 | 604 | 0.950 |
Why?
|
| Overweight | 4 | 2019 | 2371 | 0.950 |
Why?
|
| Lactones | 3 | 2016 | 329 | 0.930 |
Why?
|
| Serotonin 5-HT2 Receptor Agonists | 2 | 2019 | 31 | 0.800 |
Why?
|
| Secondary Prevention | 6 | 2017 | 1530 | 0.800 |
Why?
|
| Appetite Depressants | 2 | 2019 | 110 | 0.790 |
Why?
|
| Heart-Assist Devices | 4 | 2020 | 1194 | 0.770 |
Why?
|
| C-Reactive Protein | 3 | 2018 | 3778 | 0.740 |
Why?
|
| Pyridines | 4 | 2016 | 2825 | 0.730 |
Why?
|
| Double-Blind Method | 18 | 2020 | 12026 | 0.720 |
Why?
|
| Cardiovascular Diseases | 10 | 2020 | 15165 | 0.580 |
Why?
|
| Obesity | 5 | 2019 | 12745 | 0.580 |
Why?
|
| Serine Proteinase Inhibitors | 1 | 2018 | 179 | 0.570 |
Why?
|
| Extracorporeal Membrane Oxygenation | 4 | 2020 | 1354 | 0.520 |
Why?
|
| Atherosclerosis | 4 | 2020 | 3445 | 0.500 |
Why?
|
| Receptor, IGF Type 1 | 4 | 2006 | 390 | 0.480 |
Why?
|
| Stroke | 6 | 2020 | 9981 | 0.470 |
Why?
|
| Dyslipidemias | 2 | 2018 | 849 | 0.460 |
Why?
|
| Clinical Chemistry Tests | 1 | 2013 | 61 | 0.460 |
Why?
|
| Weight Loss | 4 | 2019 | 2622 | 0.450 |
Why?
|
| Hemodynamics | 3 | 2020 | 4199 | 0.430 |
Why?
|
| Disease Management | 3 | 2020 | 2459 | 0.410 |
Why?
|
| Heart Diseases | 3 | 2019 | 2788 | 0.410 |
Why?
|
| Registries | 5 | 2020 | 8089 | 0.410 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2015 | 342 | 0.390 |
Why?
|
| Hypoglycemia | 1 | 2018 | 861 | 0.390 |
Why?
|
| Risk Assessment | 10 | 2019 | 23338 | 0.380 |
Why?
|
| Biological Assay | 1 | 2013 | 652 | 0.360 |
Why?
|
| Ischemic Attack, Transient | 1 | 2015 | 935 | 0.350 |
Why?
|
| Critical Illness | 2 | 2019 | 2670 | 0.350 |
Why?
|
| Thiazoles | 1 | 2016 | 1483 | 0.330 |
Why?
|
| Aged | 29 | 2020 | 163280 | 0.330 |
Why?
|
| Troponin T | 1 | 2013 | 754 | 0.320 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2018 | 1790 | 0.320 |
Why?
|
| Lipids | 1 | 2019 | 3305 | 0.310 |
Why?
|
| Middle Aged | 31 | 2020 | 213383 | 0.310 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 3133 | 0.310 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 3240 | 0.310 |
Why?
|
| North America | 3 | 2020 | 1249 | 0.300 |
Why?
|
| Diabetes Mellitus, Type 2 | 4 | 2018 | 11725 | 0.300 |
Why?
|
| Risk Factors | 17 | 2020 | 72290 | 0.290 |
Why?
|
| Hypoglycemic Agents | 1 | 2018 | 2872 | 0.270 |
Why?
|
| Treatment Outcome | 17 | 2020 | 63114 | 0.270 |
Why?
|
| Myocardial Ischemia | 1 | 2016 | 2148 | 0.260 |
Why?
|
| Drug Therapy, Combination | 6 | 2019 | 6489 | 0.250 |
Why?
|
| Kidney | 2 | 2019 | 7186 | 0.240 |
Why?
|
| Male | 32 | 2020 | 350118 | 0.240 |
Why?
|
| Healthcare Disparities | 1 | 2019 | 3158 | 0.240 |
Why?
|
| Survival Rate | 7 | 2020 | 12788 | 0.230 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2016 | 3068 | 0.230 |
Why?
|
| Female | 33 | 2020 | 380194 | 0.230 |
Why?
|
| Hyphae | 1 | 2003 | 56 | 0.230 |
Why?
|
| Vacuoles | 1 | 2003 | 230 | 0.210 |
Why?
|
| Humans | 46 | 2020 | 744343 | 0.210 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2013 | 1536 | 0.210 |
Why?
|
| Antibodies, Monoclonal | 2 | 2018 | 9274 | 0.210 |
Why?
|
| Receptor, Angiotensin, Type 2 | 1 | 2020 | 67 | 0.180 |
Why?
|
| Aortic Valve Stenosis | 1 | 2013 | 1965 | 0.180 |
Why?
|
| Creatinine | 2 | 2016 | 1919 | 0.180 |
Why?
|
| Candida albicans | 1 | 2003 | 394 | 0.180 |
Why?
|
| Recurrence | 3 | 2017 | 8340 | 0.180 |
Why?
|
| Hospitalization | 1 | 2019 | 10262 | 0.180 |
Why?
|
| Time Factors | 7 | 2020 | 40075 | 0.170 |
Why?
|
| Chloroquine | 1 | 2020 | 280 | 0.160 |
Why?
|
| Critical Care | 3 | 2020 | 2647 | 0.160 |
Why?
|
| Comprehensive Health Care | 1 | 2019 | 127 | 0.160 |
Why?
|
| Hospital Mortality | 4 | 2020 | 5317 | 0.160 |
Why?
|
| Appetite Regulation | 1 | 2019 | 88 | 0.160 |
Why?
|
| Takotsubo Cardiomyopathy | 1 | 2020 | 125 | 0.160 |
Why?
|
| Adenosine Monophosphate | 1 | 2020 | 275 | 0.160 |
Why?
|
| Growth Differentiation Factor 15 | 1 | 2019 | 176 | 0.160 |
Why?
|
| Inflammation | 1 | 2018 | 10638 | 0.160 |
Why?
|
| Cardiology Service, Hospital | 1 | 2020 | 246 | 0.160 |
Why?
|
| Alanine | 1 | 2020 | 572 | 0.150 |
Why?
|
| Renal Replacement Therapy | 1 | 2020 | 257 | 0.150 |
Why?
|
| RNA, Small Interfering | 2 | 2006 | 3505 | 0.150 |
Why?
|
| Canada | 2 | 2020 | 2065 | 0.150 |
Why?
|
| Follow-Up Studies | 5 | 2020 | 39050 | 0.140 |
Why?
|
| Plasma | 1 | 2020 | 575 | 0.140 |
Why?
|
| Organizational Innovation | 1 | 2020 | 559 | 0.140 |
Why?
|
| Adamantane | 1 | 2017 | 173 | 0.140 |
Why?
|
| Hydroxychloroquine | 1 | 2020 | 412 | 0.140 |
Why?
|
| Proportional Hazards Models | 4 | 2020 | 12354 | 0.140 |
Why?
|
| Virus Internalization | 1 | 2020 | 501 | 0.140 |
Why?
|
| Metabolic Clearance Rate | 1 | 2016 | 380 | 0.140 |
Why?
|
| Pandemics | 3 | 2020 | 8388 | 0.130 |
Why?
|
| Dipeptides | 1 | 2017 | 409 | 0.130 |
Why?
|
| Receptors, Thrombin | 1 | 2015 | 131 | 0.130 |
Why?
|
| Calibration | 1 | 2017 | 816 | 0.130 |
Why?
|
| Patient Admission | 2 | 2019 | 1380 | 0.130 |
Why?
|
| Receptor, PAR-1 | 1 | 2015 | 113 | 0.120 |
Why?
|
| Cell Cycle | 1 | 2003 | 2967 | 0.120 |
Why?
|
| Endpoint Determination | 1 | 2017 | 601 | 0.120 |
Why?
|
| Incidence | 5 | 2020 | 20947 | 0.120 |
Why?
|
| Hemorrhage | 2 | 2016 | 3461 | 0.120 |
Why?
|
| Prospective Studies | 5 | 2019 | 53288 | 0.120 |
Why?
|
| Aortic Valve Insufficiency | 1 | 2018 | 579 | 0.120 |
Why?
|
| Kidney Function Tests | 1 | 2016 | 684 | 0.120 |
Why?
|
| Azetidines | 1 | 2015 | 142 | 0.120 |
Why?
|
| Placebo Effect | 1 | 2017 | 502 | 0.120 |
Why?
|
| Thrombophilia | 1 | 2016 | 305 | 0.110 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2017 | 293 | 0.110 |
Why?
|
| Interdisciplinary Communication | 1 | 2019 | 950 | 0.110 |
Why?
|
| Antimalarials | 1 | 2020 | 905 | 0.110 |
Why?
|
| Hypercholesterolemia | 1 | 2020 | 1151 | 0.110 |
Why?
|
| Prediabetic State | 1 | 2018 | 499 | 0.110 |
Why?
|
| Cerebral Revascularization | 1 | 2015 | 238 | 0.110 |
Why?
|
| Remission Induction | 1 | 2018 | 2386 | 0.110 |
Why?
|
| Limit of Detection | 1 | 2013 | 265 | 0.110 |
Why?
|
| Electrocardiography | 2 | 2016 | 6442 | 0.110 |
Why?
|
| Morbidity | 1 | 2018 | 1769 | 0.110 |
Why?
|
| Troponin I | 1 | 2016 | 619 | 0.110 |
Why?
|
| Tissue and Organ Procurement | 1 | 2020 | 896 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2019 | 6538 | 0.100 |
Why?
|
| Neurology | 1 | 2019 | 763 | 0.100 |
Why?
|
| Myocardial Revascularization | 1 | 2015 | 841 | 0.100 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2019 | 941 | 0.100 |
Why?
|
| Glomerular Filtration Rate | 1 | 2019 | 2170 | 0.100 |
Why?
|
| Tissue Donors | 1 | 2020 | 2240 | 0.090 |
Why?
|
| Internationality | 1 | 2015 | 1003 | 0.090 |
Why?
|
| Recovery of Function | 1 | 2019 | 2925 | 0.090 |
Why?
|
| Drug Monitoring | 1 | 2015 | 956 | 0.080 |
Why?
|
| Peripheral Arterial Disease | 1 | 2020 | 1188 | 0.080 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2020 | 2073 | 0.080 |
Why?
|
| Cardiology | 1 | 2019 | 1668 | 0.080 |
Why?
|
| Atrial Fibrillation | 2 | 2017 | 5034 | 0.080 |
Why?
|
| Warfarin | 1 | 2016 | 1496 | 0.080 |
Why?
|
| Comorbidity | 3 | 2018 | 10388 | 0.080 |
Why?
|
| RNA, Messenger | 1 | 2003 | 13033 | 0.080 |
Why?
|
| Antiviral Agents | 1 | 2020 | 2987 | 0.080 |
Why?
|
| Hypertension, Pulmonary | 1 | 2018 | 1537 | 0.080 |
Why?
|
| Body Weight | 1 | 2018 | 4669 | 0.080 |
Why?
|
| Kidney Diseases | 1 | 2019 | 2149 | 0.080 |
Why?
|
| Acute Kidney Injury | 1 | 2020 | 1972 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2017 | 10943 | 0.070 |
Why?
|
| Heart Transplantation | 1 | 2020 | 3110 | 0.070 |
Why?
|
| History, 21st Century | 1 | 2013 | 1534 | 0.070 |
Why?
|
| Prosthesis Design | 1 | 2013 | 2110 | 0.070 |
Why?
|
| Life Style | 1 | 2017 | 3835 | 0.070 |
Why?
|
| Echocardiography | 1 | 2018 | 5102 | 0.060 |
Why?
|
| History, 20th Century | 1 | 2013 | 2740 | 0.060 |
Why?
|
| Disease Progression | 2 | 2019 | 13284 | 0.060 |
Why?
|
| Prognosis | 3 | 2019 | 29063 | 0.060 |
Why?
|
| Heart Valve Prosthesis | 1 | 2013 | 1488 | 0.060 |
Why?
|
| Risk | 1 | 2016 | 9687 | 0.060 |
Why?
|
| Aged, 80 and over | 3 | 2018 | 57776 | 0.060 |
Why?
|
| Sex Factors | 2 | 2017 | 10397 | 0.060 |
Why?
|
| Forecasting | 1 | 2013 | 2951 | 0.060 |
Why?
|
| United States | 4 | 2020 | 69872 | 0.060 |
Why?
|
| RNA, Antisense | 1 | 2003 | 138 | 0.060 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 1 | 2003 | 112 | 0.060 |
Why?
|
| Age Factors | 1 | 2019 | 18370 | 0.050 |
Why?
|
| Patient Discharge | 1 | 2015 | 3313 | 0.050 |
Why?
|
| Survival Analysis | 1 | 2015 | 10252 | 0.050 |
Why?
|
| Research Design | 1 | 2018 | 5987 | 0.050 |
Why?
|
| Nitrogen | 1 | 2003 | 344 | 0.050 |
Why?
|
| Serum | 1 | 2003 | 214 | 0.050 |
Why?
|
| Hydroxyurea | 1 | 2003 | 290 | 0.050 |
Why?
|
| G1 Phase | 1 | 2003 | 415 | 0.050 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 5319 | 0.050 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 15540 | 0.050 |
Why?
|
| Antineoplastic Agents | 2 | 2006 | 13695 | 0.050 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2003 | 433 | 0.050 |
Why?
|
| Culture Media | 1 | 2003 | 908 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 3 | 2006 | 6314 | 0.050 |
Why?
|
| Anticoagulants | 1 | 2016 | 4599 | 0.050 |
Why?
|
| Patient Selection | 1 | 2013 | 4215 | 0.050 |
Why?
|
| Gene Silencing | 2 | 2006 | 1538 | 0.050 |
Why?
|
| Body Mass Index | 1 | 2017 | 12720 | 0.040 |
Why?
|
| Diet | 1 | 2017 | 7939 | 0.040 |
Why?
|
| Nucleic Acid Conformation | 1 | 2003 | 913 | 0.040 |
Why?
|
| Diabetes Mellitus | 1 | 2017 | 5751 | 0.040 |
Why?
|
| Radiation Tolerance | 1 | 2001 | 486 | 0.040 |
Why?
|
| Civil Defense | 1 | 2020 | 109 | 0.040 |
Why?
|
| Organizational Objectives | 1 | 2020 | 438 | 0.040 |
Why?
|
| Melanoma, Experimental | 1 | 2001 | 561 | 0.040 |
Why?
|
| Coronary Artery Disease | 1 | 2017 | 6487 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2013 | 15076 | 0.040 |
Why?
|
| Cattle | 1 | 2003 | 3922 | 0.040 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2006 | 2043 | 0.030 |
Why?
|
| Shock | 1 | 2018 | 318 | 0.030 |
Why?
|
| Cell Division | 1 | 2003 | 4568 | 0.030 |
Why?
|
| Diet, Reducing | 1 | 2019 | 462 | 0.030 |
Why?
|
| Kinetics | 1 | 2003 | 6473 | 0.030 |
Why?
|
| Aorta | 1 | 2003 | 2061 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2017 | 40561 | 0.030 |
Why?
|
| RNA Interference | 1 | 2003 | 2889 | 0.030 |
Why?
|
| Neoplasms | 1 | 2003 | 21683 | 0.030 |
Why?
|
| Catheterization | 1 | 2019 | 1470 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2001 | 3002 | 0.030 |
Why?
|
| Adult | 2 | 2018 | 214055 | 0.030 |
Why?
|
| Cooperative Behavior | 1 | 2019 | 1504 | 0.030 |
Why?
|
| Risk Reduction Behavior | 1 | 2019 | 1125 | 0.030 |
Why?
|
| Endothelial Cells | 1 | 2003 | 3479 | 0.020 |
Why?
|
| Consensus | 1 | 2019 | 2959 | 0.020 |
Why?
|
| Respiratory Insufficiency | 1 | 2018 | 1199 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2001 | 3703 | 0.020 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2018 | 2268 | 0.020 |
Why?
|
| Heart Arrest | 1 | 2018 | 1470 | 0.020 |
Why?
|
| Melanoma | 1 | 2006 | 5510 | 0.020 |
Why?
|
| Triglycerides | 1 | 2015 | 2454 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2003 | 19229 | 0.020 |
Why?
|
| Coronary Artery Bypass | 1 | 2016 | 2289 | 0.020 |
Why?
|
| Transfection | 2 | 2006 | 5892 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2001 | 8428 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2018 | 3679 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2006 | 625 | 0.010 |
Why?
|
| Quality Improvement | 1 | 2018 | 3749 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2019 | 8554 | 0.010 |
Why?
|
| Melanocytes | 1 | 2006 | 515 | 0.010 |
Why?
|
| Animals | 3 | 2003 | 168757 | 0.010 |
Why?
|
| Oligodeoxyribonucleotides, Antisense | 1 | 2001 | 57 | 0.010 |
Why?
|
| Point Mutation | 1 | 2006 | 1623 | 0.010 |
Why?
|
| Ataxia Telangiectasia | 1 | 2001 | 112 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 25043 | 0.010 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2006 | 1692 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2006 | 2503 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 2001 | 2085 | 0.010 |
Why?
|
| Cell Survival | 1 | 2006 | 5882 | 0.010 |
Why?
|
| Heart Failure | 1 | 2019 | 10900 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2001 | 3701 | 0.010 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2001 | 1990 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2020 | 77449 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2006 | 5172 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2001 | 8436 | 0.010 |
Why?
|
| Skin Neoplasms | 1 | 2006 | 5686 | 0.000 |
Why?
|
| Apoptosis | 1 | 2001 | 9727 | 0.000 |
Why?
|
| Phenotype | 1 | 2001 | 16365 | 0.000 |
Why?
|
| Mice, Inbred C57BL | 1 | 2001 | 21827 | 0.000 |
Why?
|
| Signal Transduction | 1 | 2006 | 23403 | 0.000 |
Why?
|
| Mice | 1 | 2001 | 81183 | 0.000 |
Why?
|